Pancreatic Enzymes
Best-in-class: Dipan-9
Thorne Dipan-9. One active, at strength: pancreatin 1 g per two-capsule serving, declaring amylase 112,500 USP units, protease 115,000 USP units and lipase 17,500 USP units. There is no ox bile and no betaine HCl in it, which is the difference between this and Bio-Gest.
Pancreatic Enzymes quick facts
| Suggested dose | With meals, per practitioner guidance. |
| How often | With every meal containing fat or protein |
| Who it's for | Sluggish digestion, fat maldigestion, low pancreatic output. |
Where actual exocrine pancreatic insufficiency exists, this is treatment rather than supplementation, and dosing is by lipase units matched to meal fat content. Enteric coating matters — uncoated enzymes are destroyed by stomach acid unless acid is also suppressed. If steatorrhoea is the symptom, that warrants investigation rather than self-treatment.
How Pancreatic Enzymes actually works
Higher-potency porcine-derived lipase, protease and amylase — the clinical-grade version, dosed by lipase units. Lipase is the one that matters most, since fat maldigestion causes the pale, floating, foul stools that signal genuine insufficiency and the fat-soluble vitamin deficiencies that follow.
Where to get Pancreatic Enzymes
Buy Dipan-9 at Thorne →The evidence for Pancreatic Enzymes
Graded by what exists behind each claim.
✅ Clinically validated
- Pancreatic enzyme replacement is established for exocrine pancreatic insufficiency (improves digestion and nutrient absorption).
- Reduces maldigestion symptoms (bloating, floating/greasy stools) when enzyme output is low.
📊 Correlative data
- Fat maldigestion symptoms track with low pancreatic enzyme output.
🧪 Theoretical / extrapolated benefits
- Routine use in healthy people is less evidence-backed than in true insufficiency.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Pancreatic Enzymes actually does
Pancreatin is not a supplement ingredient in the ordinary sense. It is a defatted extract of porcine pancreas carrying the three enzyme classes the organ secretes, and the only one that matters clinically is the lipase. Pancreatic triacylglycerol lipase cleaves the sn-1 and sn-3 ester bonds of a triglyceride to leave two free fatty acids and a 2-monoacylglycerol, and it cannot do that alone: bile salts coat the emulsion droplet and displace it, so lipase needs colipase, a small cofactor protein that anchors the enzyme to the bile-salt-covered lipid-water interface. A capsule that supplies lipase is supplying half a system that also needs bile and an alkaline duodenum.
Lipase is the fragile one, and there is a measurement that shows exactly why. When enzyme survival was tracked along the human intestine, the different classes did not behave alike — lipase is destroyed intraluminally far faster than trypsin or amylase, so the proportion of secreted lipase still active in the distal small bowel is a small fraction of what left the pancreas Layer 1993. Its own companions digest it. That single asymmetry is why exocrine pancreatic insufficiency presents as fat maldigestion first and protein maldigestion much later, and why every replacement product is dosed in lipase units rather than in milligrams.
The organ has an enormous reserve, and the number is the reason this is a real indication rather than a wellness one. Steatorrhea does not appear until pancreatic enzyme output falls below roughly a tenth of normal — which means a person with meaningful pancreatic damage can still digest fat, and a person with normal output cannot be helped by more enzyme, because the enzyme was never the limiting step Dominguez-Munoz 2024. Exocrine pancreatic insufficiency is a diagnosis, made with fecal elastase-1 — below 200 micrograms per gram of stool is the usual cut-off, below 100 severe Dominguez-Munoz 2024.
The outcome measure is arithmetic, not a feeling. The coefficient of fat absorption is fat eaten minus fat excreted, divided by fat eaten: run a measured fat intake for several days, collect everything, and the answer is a percentage. Healthy absorption is above roughly 93%, and the entire clinical case for pancreatic enzyme replacement is built on moving that number Whitcomb 2010. The 13C-mixed triglyceride breath test is the non-collection version of the same question and was validated specifically to check whether a given enzyme dose had actually normalized fat digestion in chronic pancreatitis Dominguez-Munoz 2007.
Stomach acid is the second half of the mechanism. Lipase is irreversibly inactivated at acid pH, which is why prescription pancrelipase is formulated as enteric-coated microspheres that stay closed in the stomach and dissolve above about pH 5.5 in the duodenum Case 2005. It is also why acid suppression is a recognized adjunct when replacement fails: in insufficiency, bicarbonate output falls with enzyme output, the duodenum stays acidic, and the coating never opens Dominguez-Munoz 2011.
Cell, rodent, human — and where it stops
This category has no cell-to-rodent chain, and pretending otherwise would be the dishonest version. Nobody needed a mouse to believe that swallowed lipase digests fat. The chain that matters runs from a dissolution vessel to an intraluminal perfusion study to a stool collection, and each step subtracts something.
In the vessel. Enteric-coated pancreatic enzyme products were assayed for declared versus actual content and for acid stability before the 2010 US approvals; the finding that should be on every label is that batches varied, with one showing only 8% of expected lipase activity after acid exposure Case 2005. The unit on the bottle is a claim about a batch, not a physical constant.
In the human intestine. The survival study is the step everyone skips: lipase is preferentially degraded in the lumen relative to the other pancreatic enzymes Layer 1993. Any dose calculated as though swallowed lipase arrives intact is calculated wrong.
In the trial. Delayed-release pancrelipase in exocrine pancreatic insufficiency from chronic pancreatitis or pancreatic surgery, double-blind and placebo-controlled: 25 patients on enzyme against 29 on placebo, with the coefficient of fat absorption rising 31.9 ± 18.6% on treatment against 8.7 ± 12.4% on placebo, P < 0.0001, and the coefficient of nitrogen absorption rising 35.2 ± 29.1% against 8.9 ± 28.0%, P = 0.0005 Whitcomb 2010. Adverse events were 20.0% against 20.7% — the same in both arms.
The obstacle is the dose, and it is arithmetic anyone can check. European guidance for pancreatic exocrine insufficiency is 40,000 to 50,000 units of lipase with a main meal and half that with a snack Dominguez-Munoz 2024 Lohr 2017. This product's own filed label declares 17,500 USP units of lipase per two-capsule serving NIH DSLD record 2026. Reaching the low end of the guideline dose therefore takes about five capsules with every main meal, and reaching the top of it takes six — against a card that says “with meals, per practitioner guidance” and a bottle whose suggested use is one to two capsules NIH DSLD record 2026. One or two capsules is 8,750 to 17,500 units, which is a fifth to a little over a third of a meal dose.
The second obstacle is that the filed label names no enteric coating. The other-ingredient line is hypromellose — a capsule shell NIH DSLD record 2026. The trial product was an enteric-coated delayed-release formulation Whitcomb 2010, and enteric coating exists because unprotected lipase does not survive gastric acid Case 2005. A reader taking an uncoated product at a fifth of the trial dose is running neither the dose nor the formulation that produced the 31.9% figure.
Pancreatic Enzymes — which form, and does it matter
A USP lipase unit is an activity, not a mass, and that is the only number worth reading. The label declares 1 gram of pancreatin per two capsules and separately declares what that gram does: 112,500 USP units of amylase, 115,000 of protease, 17,500 of lipase NIH DSLD record 2026. Milligrams of pancreatin tell you nothing, because the activity per gram varies with the extract. Compare products on lipase units per capsule or do not compare them.
Amylase and protease are the decoys. They are declared in six-figure numbers and the lipase in five, which reads as generosity and is instead the shape of the underlying material: pancreas is rich in proteases. Since fat is the nutrient that fails first Dominguez-Munoz 2024 and lipase is the enzyme that is destroyed fastest Layer 1993, the impressive numbers are on the two enzymes that were not the problem.
Enteric coating is a therapeutic decision, not packaging. Coated microspheres small enough to leave the stomach with the meal are the prescription design, and the dissolution behavior of those coatings is what the in vitro assay work was about Case 2005. Uncoated pancreatin has one legitimate use pattern — taken with a proton-pump inhibitor so the stomach is not acidic enough to destroy it — and that combination is a prescribing decision Dominguez-Munoz 2011, not a supplement instruction.
Porcine, and it matters twice. Pancreatin is pig pancreas: relevant to anyone avoiding pork for dietary or religious reasons, and relevant to the microbiological standards the raw material is held to. Fungal lipases from Rhizopus and Aspergillus are the vegetarian alternative and they are a different enzyme with a different pH optimum; the coefficient-of-fat-absorption evidence belongs to porcine pancrelipase Whitcomb 2010, not to them.
Timing is part of the dose. Enzyme has to be in the same place at the same time as the meal, so the guideline position is with food, distributed through the meal rather than swallowed before it Dominguez-Munoz 2024. Taken on an empty stomach it is a protein supplement with no substrate.
What would have to be true, and how you would know it was not
1. If this is genuine insufficiency, the marker is stool fat and the window is one week. Predict the coefficient of fat absorption rises by something in the order of 20 to 30 percentage points once the dose reaches 40,000–50,000 lipase units per main meal Whitcomb 2010 Dominguez-Munoz 2024. Retest after seven days at the full dose — a 72-hour collection, or the 13C-mixed triglyceride breath test if you would rather not Dominguez-Munoz 2007. The cheap proxy is a symptom diary with a defined baseline: count stools per day, and count the days with visible oil or a floating, foul, hard-to-flush stool, for seven days before and seven days on.
2. The prediction that cuts against this product as sold. At one to two capsules per meal — 8,750 to 17,500 lipase units NIH DSLD record 2026 — predict the coefficient of fat absorption does not normalize, because that is a fifth to a third of the dose the trials used Whitcomb 2010. Predict that someone who feels better anyway did not have exocrine pancreatic insufficiency, and predict that a person who does have it and stops at two capsules stays malnourished while feeling reassured.
3. The test that should come first, and the number it has to beat. Fecal elastase-1 above 200 micrograms per gram makes pancreatic insufficiency unlikely and makes this product the wrong answer to whatever the symptom is Dominguez-Munoz 2024. It is a single stool sample. Predict that most people who buy pancreatic enzymes for bloating have a normal result.
4. Fat-soluble vitamins are the delayed confirmation, and they are slow. If fat absorption genuinely improves, predict 25-OH vitamin D and vitamin A drift upward over three to six months in someone who was deficient because of malabsorption — and predict nothing at all in someone whose levels were normal, because a marker with no deficit cannot correct. Predict serum lipase and amylase do not move at all: they measure pancreatic injury, not swallowed enzyme.
What nobody has tested yet
Nobody has run the trial this bottle implies. Every coefficient-of-fat-absorption result belongs to enteric-coated pancrelipase in diagnosed insufficiency Whitcomb 2010. Nobody has randomized people with normal fecal elastase and post-meal bloating to an uncoated pancreatin at label dose against placebo, with a stool-fat endpoint. That trial is cheap, it is obvious, and its absence is the reason this page cannot tell a well person what to expect.
Nobody has published the dose-response curve. The guideline number — 40,000 to 50,000 units per meal Dominguez-Munoz 2024 — is a starting dose derived from replacing physiological output, not a measured plateau. What fraction of the coefficient-of-fat-absorption benefit survives at 20,000 units, or at 10,000, has never been mapped, which means nobody can say where on that curve a five-capsule habit actually sits.
Nobody has measured what an uncoated capsule delivers past the pylorus. The acid-stability work was done on coated products in vitro Case 2005 and the survival work on endogenous enzyme in vivo Layer 1993. The specific number for this product — units of lipase activity recoverable in duodenal aspirate after a labeled dose of uncoated pancreatin, with and without a proton-pump inhibitor — would settle the argument in one small study and has never been produced.
And nobody knows the safe ceiling outside cystic fibrosis. The dose cap that governs enzyme prescribing came from fibrosing colonopathy in children with cystic fibrosis FitzSimmons 1997 Smyth 1995. Whether the same ceiling applies to an adult without cystic fibrosis, and whether the injury was the lipase, the coating polymer or the underlying disease, was never resolved — the products were simply capped and the question was dropped.
Pancreatic Enzymes — its own safety story, not its category's
The complication that shaped this whole category has a name and a dose. Fibrosing colonopathy — stricturing of the ascending colon — appeared in children with cystic fibrosis taking high-strength pancreatic enzymes, and two case-control studies tied it to enzyme dose FitzSimmons 1997 Smyth 1995. The consequence is the reason prescription dosing is weight-based and capped rather than open-ended, and it is the single strongest argument against the idea that more enzyme is harmlessly better.
The specific harm of a supplement-strength product is the opposite one, and it is quieter. A person with real insufficiency who takes 17,500 lipase units a meal NIH DSLD record 2026 instead of 40,000 to 50,000 Dominguez-Munoz 2024 continues to malabsorb fat, and therefore continues to malabsorb vitamins A, D, E and K, while believing the problem is being treated. Untreated exocrine pancreatic insufficiency carries measurable nutritional and bone consequences over years; the damage here is done by the delay, not by the capsule.
Porcine tissue, and a purine load. Pancreatin is animal pancreas, which is nucleoprotein-rich; hyperuricosuria and raised uric acid are recognized on prescription pancrelipase labeling at therapeutic doses, which is a live consideration in gout. It is also pork — a real issue for dietary restriction and for pork allergy — and it is a biological raw material, so viral safety and microbiological control are properties of the manufacturer rather than of the molecule.
Active proteases in the mouth are a mucosal irritant. The declared 115,000 USP units of protease per serving NIH DSLD record 2026 are active enzyme, not zymogen: a capsule chewed, opened onto food, or left dissolving under the tongue puts trypsin-like activity on oral mucosa, which is the mechanism behind the stomatitis reported with these products. Swallow them whole with the meal.
Iron and the acid question. Pancreatic enzyme preparations reduce iron absorption, and the ordinary workaround — adding a proton-pump inhibitor so the enzyme survives Dominguez-Munoz 2011 — lowers non-heme iron absorption further. Anyone on this combination with a low ferritin has two reasons for it, and neither is dietary.
Sources read for this page
- NIH DSLD record. Dipan-9 (Thorne), on-market label record: pancreatin 1 g per 2-capsule serving, declaring amylase 112,500 USP units, protease 115,000 USP units and lipase 17,500 USP units; other ingredient hypromellose. NIH Dietary Supplement Label Database, DSLD ID 231262, retrieved 2026
- Whitcomb DC. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. Am J Gastroenterol 2010 · PMID 20502447
- Layer P. Fate of pancreatic enzymes in the human intestinal lumen in health and pancreatic insufficiency. Digestion 1993 · PMID 7693530
- Case CL. Enzyme content and acid stability of enteric-coated pancreatic enzyme products in vitro. Pancreas 2005 · PMID 15714141
- Dominguez-Munoz JE. European guidelines for the diagnosis and treatment of pancreatic exocrine insufficiency: UEG, EPC, EDS, ESPEN, ESPGHAN, ESDO, and ESPCG evidence-based recommendations. United European Gastroenterol J 2024 · PMID 39639485
- Lohr JM. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J 2017 · PMID 28344786
- Dominguez-Munoz JE. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency: when is it indicated, what is the goal and how to do it?. Adv Med Sci 2011 · PMID 21450558
- Dominguez-Munoz JE. 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2007 · PMID 17445754
- FitzSimmons SC. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997 · PMID 9113931
- Smyth RL. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995 · PMID 7475715
How you would know if it worked
Serum lipase and amylase measure pancreatic injury, not enzyme replacement — swallowing enzymes does not move them, so they are the wrong numbers for this product. The read-out of replacement working is nutritional: supplemental lipase is what allows the fat-soluble vitamins to be absorbed, and pancreatic proteases are what release B12 from the carrier protein it arrives bound to so intrinsic factor can take it on.
- Vitamin A Retest: 12 weeks after changing intake.
- Vitamin D (25-Hydroxy) Retest: 8–12 weeks after a dose change; then every 6–12 months.
- Vitamin B12 Retest: 8–12 weeks after starting supplementation.
The cheapest panel carrying Vitamin D (25-Hydroxy) and at least one other of these is Mood, Anxiety & Low Motivation, at $202 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Pancreatic Enzymes — safety & side effects
- GI upset. At high doses in cystic fibrosis, fibrosing colonopathy is a documented complication — this is why prescription dosing is weight-based and capped.
- Porcine-derived — relevant for dietary restriction and pork allergy.
- Pancreatic insufficiency needs a diagnosis and a prescription dose. A supplement is not equivalent to the enteric-coated prescription product.
- Raises uric acid; caution with gout. Reduces iron absorption.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Pancreatic Enzymes in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pancreatic Enzymes
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Uric Acid | High-dose enzyme preparations raise urate — relevant if you have gout |
| Comprehensive Metabolic Panel (CMP) | Liver and pancreatic context |
| Ferritin | Malabsorption shows up as iron deficiency first |
| Vitamin B12 | And as B12 deficiency, if absorption is the real problem |
The Gut Health & Absorption panel covers these in one order — 11 markers, $208.80 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pancreatic Enzymes — frequently asked questions
What is Pancreatic Enzymes?
Thorne Dipan-9. One active, at strength: pancreatin 1 g per two-capsule serving, declaring amylase 112,500 USP units, protease 115,000 USP units and lipase 17,500 USP units. There is no ox bile and no betaine HCl in it, which is the difference between this and Bio-Gest.
What is the suggested dose of Pancreatic Enzymes?
With meals, per practitioner guidance. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Pancreatic Enzymes dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Pancreatic Enzymes?
Coach Cam sources Pancreatic Enzymes from Thorne, with 10% off auto-applied at checkout — use the buy link on this page.
Pancreatic Enzymes inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Pancreatic Enzymes is used for
Pancreatic Enzymes appears under 1 goal in the goal router.
Related Gut & Digestion supplements
Where this goes next
Pancreatic Enzymes is the digestive-output arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.